Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Immunocore Holdings plcNASDAQ: IMCR

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow dips below year-ago levels

Q1 FY2026 financing cash flow of $654.9K fell 74.3% year over year, behind the +121.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 84.7% from the prior quarter. Over 3 fiscal years it compounded at -60.2% a year.

Context

  • Financing cash flow amounted to 3.1% of revenue in FY2025, down 135.6 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -74.3% toward the trailing-twelve-month pace of +121.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$654.9K-84.7% QoQ
Last fiscal yearDec 2025
$9.2M-97.3% YoY
LTMMar 2026
$10.47M+121.3% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.3%——
1 year-97.3%——
3-year CAGR-60.2%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

Mixed currencies · from the cash flow

Latest · FY2025
9.2M USD
Year-over-year change
-97.3%

Financing Cash Flow vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +121.3% is the 4th highest of 10, against a peer median of -16.8%.
  • Financing cash flow amounts to 2.7% of revenue for IMCR, versus a peer median of 40.5%.
IMCR Competitors
Financing Cash Flow for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$376.3M USD-16.8%+19.7%206.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$313M USD+30.4%+145.5%267.5%
IMTXImmatics N.V.LTM Mar 2026€118.48M EUR-17.9%-8.9%317.7%
BNTXBioNTech SELTM Jun 2026€112.12M EUR+142.6%-67.0%4.2%
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M USD+16083.5%+247.3%44.3%
IMCRImmunocore Holdings plcLTM Mar 2026$10.47M USD+121.3%-60.2%2.7%
XNCRXencor, Inc.LTM Jun 2026$8.3M USD-95.9%+13.0%7.9%
JANXJanux Therapeutics, Inc.LTM Mar 2026$7.94M USD-98.0%+114.7%36.7%
IPHAInnate Pharma S.A.FY2025€5.83M EUR+197.0%—209.2%
IMMPImmutep LimitedFY2025A$525.12K AUD-100.6%—10.4%
CGENCompugen Ltd.LTM Dec 2025$0 USD—+210.9%0.0%
Peer median (excluding IMCR) —-16.8%+67.2%40.5%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(180.03M)(52.54M)(34.32M)(51.09M)(26.42M)
Depreciation & Amortization7.59M5.34M3.24M4.2M2.43M
Deferred Income Tax(12.69M)(3.53M)0011M
Stock-Based Compensation48.89M32.89M25.69M34.19M0
Change in Working Capital(21.96M)(24.17M)4.58M45.13M(6.92M)
Accounts Receivables(4.86M)(26.26M)(14.14M)(12.35M)(5.46M)
Inventory00000
Accounts Payables1.47M4.91M2.08M7.27M(1.83M)
Other Working Capital(18.57M)(2.81M)16.64M50.21M366K
Other Non-Cash Items15.09M(7.19M)3.14M(6.38M)11.94M
Operating Cash Flow(143.11M)(49.21M)2.33M26.06M(7.97M)
Capital Expenditures(1.39M)(2.2M)(4.29M)(5.17M)(3.23M)
Acquisitions (Net)00000
Purchases of Investments000(350M)(22.32M)
Sales of Investments000013.39M
Other Investing Activities106K6K(925.46K)44K0
Investing Cash Flow(1.28M)(2.2M)(4.29M)(355.13M)(12.16M)
Debt Repayment000352.5M0
Common Stock Issued286.89M139.52M06.8M9.2M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.3M5.93M27.18M(15.42M)0
Financing Cash Flow288.19M145.44M27.18M343.88M9.2M
Effect of Forex Changes625K(12.65M)6.56M(1.71M)19.81M
Net Change in Cash144.42M81.39M31.78M13.11M8.89M
Free Cash Flow(144.49M)(51.41M)(1.97M)20.89M(11.2M)

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.